Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.1K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.1K
Lattice Centering and Coordination Number02:33

Lattice Centering and Coordination Number

11.7K
The structure of a crystalline solid, whether a metal or not, is best described by considering its simplest repeating unit, which is referred to as its unit cell. The unit cell consists of lattice points that represent the locations of atoms or ions. The entire structure then consists of this unit cell repeating in three dimensions. The three different types of unit cells present in the cubic lattice are illustrated in Figure 1.
Types of Unit Cells
Imagine taking a large number of identical...
11.7K
Adult Stem Cells01:33

Adult Stem Cells

33.9K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.9K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.5K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.5K
Center of Gravity00:58

Center of Gravity

6.7K
The center of gravity (COG) of an object is the point where the object's total weight is considered to be concentrated. Knowing the location of the center of gravity is useful when predicting the behavior of a moving object or designing static structures. In a uniform gravitational field, the center of gravity is similar to the center of mass (COM); yet, these two points can be positioned differently. For example, the Moon's center of mass lies very close to its geometric center, but...
6.7K
Center of Gravity01:15

Center of Gravity

2.2K
The center of gravity is the point at which an object's weight appears to be concentrated and can be used to balance the object perfectly. This point is essential in mechanics as it provides information regarding a body's stability and moments of inertia. The center of gravity does not always have to fall within the shape or boundaries of the body; it may also lie outside the body in certain cases.
To determine its location, the principle of moments can be utilized by dividing the object into...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

Bone marrow transplantation·2023
Same author

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.

Bone marrow transplantation·2023
Same author

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.

Bone marrow transplantation·2021
Same author

Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studies.

Pediatric hematology and oncology·2019
Same author

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Bone marrow transplantation·2019
Same author

Frequency of Pathologic Changes in the Oral Cavity in Patients Subjected to Long-term Pharmacologic Immunosuppressive Therapy After Kidney, Liver, and Hematopoietic Cell Transplantation.

Transplantation proceedings·2018

Related Experiment Video

Updated: Feb 5, 2026

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
06:48

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice

Published on: July 25, 2014

13.8K

Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.

E Karakulska-Prystupiuk1, J Drozd-Sokołowska1, A Waszczuk-Gajda1

  • 1Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

Transplantation Proceedings
|September 5, 2018
PubMed
Summary

Azacitidine shows promise as preemptive therapy to prevent relapse after allogeneic stem cell transplant for myeloid malignancies. Early use may improve survival and allow for a second transplant in relapsed cases.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.8K
Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 25, 2007

24.2K

Related Experiment Videos

Last Updated: Feb 5, 2026

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
06:48

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice

Published on: July 25, 2014

13.8K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.8K
Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 25, 2007

24.2K

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Relapse remains a primary cause of treatment failure in myeloid malignancies post allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • Limited therapeutic options exist for managing relapse, highlighting the need for effective strategies.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of azacitidine use in patients with myeloid malignancies undergoing or having undergone allo-HSCT.
  • To compare the effectiveness of azacitidine when used preemptively versus for overt relapse or maintenance therapy.

Main Methods:

  • A retrospective, single-institution study of 28 patients with myeloid malignancies treated with azacitidine.
  • Patients received azacitidine for overt relapse, preemptive therapy, or post-transplant maintenance.
  • Donor lymphocyte infusions (DLIs) were administered to some patients.

Main Results:

  • Preemptive azacitidine therapy was associated with significantly longer median overall survival (21.2 months) compared to relapse therapy (6.1 months).
  • In the preemptive group, 50% achieved complete cytogenetic remission and 14% had stable minimal residual disease.
  • Toxicity was observed, including neutropenia (71%), thrombocytopenia (36%), and serious infections (36%) in the preemptive setting.

Conclusions:

  • Azacitidine is most effective when used as a preemptive therapy to prevent relapse after allo-HSCT for myeloid malignancy.
  • Using azacitidine for ongoing relapse may stabilize disease and facilitate a second allo-HSCT.